Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Yanni Lou


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


Y. Lou1, L. Jia1, J. Wang2, H. Sun3, G. Yang4, R. Yu1, X. Wu1, T. He3

Author affiliations

  • 1 Oncology, China-Japan Friendship Hospital, 100029 - Beijing/CN
  • 2 Oncology, Cancer Hospital Chinese Academy of Medical Sciences, 100021 - Beijing/CN
  • 3 Tcm Oncology, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 4 Tcm Oncology, Beijing Hospital of Chinese Medicine, 100010 - Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3913


Hand-foot syndrome (HFS) is an adverse effect which triggered by chemotherapy, Capecitabine has the highest reported HFS incidence at about 50% to 60%. LC09 is composed of Chinese herbs and is used to soak hands and feet. Former clinical study and animal experiment have shown that Chinese herbal compound LC09 can alleviate numb, pain and inflammation. This study is aimed to evaluate its validity via strictly randomized, double-blind, placebo-controlled trial.


156 patients which is diagnosed as HFS randomly assigned 1:1 to treatment group (n = 78) and control group (n = 78) in 4 centers. Intervention of LC09 or placebo is lasting for 6 weeks and evaluated every week by NCI degree, NRS pain scores. Assess quality of life using DLQI (dermatology life quality index) scale and IADL (instrumental activity of daily living) scale at the beginning one week later and the end.


NCI degree and NRS pain scores between two groups are significant difference (p < 0.001). HFS effective rate (70.4%) and pain alleviated rate (81.9%) of treatment group are significantly higher than control group (p < 0.001). There is no intense evidence identify the effect for quality of life with LC09 after assessing by DLQI scale and IADL scale. Chemical completion rate between two groups is significantly different, P = 0.0021.


Chinese herbal compound LC09 can decrease NCI degree and alleviate pain significantly. Besides, it can also increase chemical completion rate. But effect for quality of life still needs to search with more specific scale.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Ministry of Science and Technology of the People’s Republic of China (2015BAI04B07).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.